Pfaar O - Search Results

1

EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.

Agache I, Lau S, Akdis CA, Smolinska S, Bonini M, Cavkaytar O, Flood B, Gajdanowicz P, Izuhara K, Kalayci O, Mosges R, Palomares O, Papadopoulos NG, Sokolowska M, Angier E, Fernandez-Rivas M, Pajno G, Pfaar O, Roberts GC, Ryan D, Sturm GJ, van Ree R, Varga EM, van Wijk RG, Yepes-Nuñez JJ, Jutel M. Agache I, et al. Among authors: pfaar o. Allergy. 2019 May;74(5):855-873. doi: 10.1111/all.13749. Allergy. 2019. PMID: 31095767

2

Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial.

Pfaar O, Klimek L. Pfaar O, et al. Ann Allergy Asthma Immunol. 2008 Mar;100(3):256-63. doi: 10.1016/s1081-1206(10)60451-6. Ann Allergy Asthma Immunol. 2008. PMID: 18426146 Clinical Trial.

3

Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens.

Pfaar O, Klimek L, Fischer I, Sieber J, Amoroso S, Moreno Aguilar C, Shah K, Mösges R. Pfaar O, et al. Int Arch Allergy Immunol. 2009;150(1):102-8. doi: 10.1159/000210436. Epub 2009 Apr 2. Int Arch Allergy Immunol. 2009. PMID: 19339808 Clinical Trial.

4

Clinical outcome measures of specific immunotherapy.

Pfaar O, Anders C, Klimek L. Pfaar O, et al. Curr Opin Allergy Clin Immunol. 2009 Jun;9(3):208-13. doi: 10.1097/ACI.0b013e32832aef57. Curr Opin Allergy Clin Immunol. 2009. PMID: 19365259 Review.

5

[Cluster immunotherapy of persistent allergic rhinoconjunctivitis. Safety aspects of induction therapy with mite depot allergen preparations].

Pfaar O, Mösges R, Hörmann K, Klimek L. Pfaar O, et al. HNO. 2009 Nov;57(11):1099-105. doi: 10.1007/s00106-009-1946-8. HNO. 2009. PMID: 19585090 German.

6

Safety aspects of Cluster immunotherapy with semi-depot allergen extracts in seasonal allergic rhinoconjunctivitis.

Pfaar O, Mösges R, Hörmann K, Klimek L. Pfaar O, et al. Eur Arch Otorhinolaryngol. 2010 Feb;267(2):245-50. doi: 10.1007/s00405-009-1077-6. Eur Arch Otorhinolaryngol. 2010. PMID: 19756683

7

Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study.

Ott H, Sieber J, Brehler R, Fölster-Holst R, Kapp A, Klimek L, Pfaar O, Merk H. Ott H, et al. Among authors: pfaar o. Allergy. 2009 Sep;64(9):1394-401. doi: 10.1111/j.1398-9995.2009.02194.x. Allergy. 2009. PMID: 19764942 Clinical Trial.

8

Safety of a depigmented, polymerized vaccine for the treatment of allergic rhinoconjunctivitis and allergic asthma.

Pfaar O, Klimek L, Sager A, Bräutigam M. Pfaar O, et al. Am J Rhinol Allergy. 2010 May-Jun;24(3):220-5. doi: 10.2500/ajra.2010.24.3437. Epub 2010 Feb 17. Am J Rhinol Allergy. 2010. PMID: 20167138 Clinical Trial.

9

Cluster protocols in SCIT: enough evidence for practical use?

Pfaar O, Leitzbach S, Hörmann K, Klimek L. Pfaar O, et al. Curr Opin Allergy Clin Immunol. 2010 Jun;10(3):188-93. doi: 10.1097/ACI.0b013e328339505c. Curr Opin Allergy Clin Immunol. 2010. PMID: 20410818 Review.

10

Immunotherapy with depigmented-polymerized mixed tree pollen extract: a clinical trial and responder analysis.

Pfaar O, Robinson DS, Sager A, Emuzyte R. Pfaar O, et al. Allergy. 2010 Dec;65(12):1614-21. doi: 10.1111/j.1398-9995.2010.02413.x. Allergy. 2010. PMID: 20645937 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

373 results

Search Page